Table 2.
GSTM1 polymorphism as a predictor for overall and cardiovascular mortality as well as death of myocardial infarction and cerebral vascular insult among 199 ESRD patients after a median follow-up time of 8 yrs by Cox proportional hazards regression models
| Model 1 a | Model 2 b | Model 3 c | |||
|---|---|---|---|---|---|
|
HR (95% CI) |
P value |
HR (95% CI) |
P value |
HR (95% CI) |
P value |
|
Risk for overall mortality comparing
GSTM1-null
homozygotes to
GSTM1-active
carriers | |||||
| 1.74 (0.96-3.14) |
0.066 |
1.88 (1.03-3.45) |
0.041 |
2.08 (1.10-3.92) |
0.024 |
|
Risk for cardiovascular mortality comparing
GSTM1-null
homozygotes to
GSTM- active
carriers | |||||
| 1.96 (0.95-4.08) |
0.070 |
2.03 (0.97-4.22) |
0.060 |
2.19 (1.01-4.79) |
0.050 |
|
Risk for death from myocardial infarction comparing
GSTM1-null
homozygotes to
GSTM1-active
carriers | |||||
| 1.70 (0.65-4.49) |
0.281 |
1.74 (0.66-4.60) |
0.263 |
1.82 (0.63-5.26) |
0.270 |
|
Risk for death from CVI comparing
GSTM1-null
homozygotes to
GSTM1-active
carriers | |||||
| 3.38 (0.96-11.94) | 0.058 | 3.54 (0.99-12.56) | 0.051 | 3.80 (1.03-14.02) | 0.045 |
Abbreviations: CI Confidence Interval, HR Hazard Ratio.
aAdjusted for age and gender.
bAdjusted for the covariates in Model 1 plus an additional adjustment for smoking status.
cAdjusted for the covariates in Model 2 plus an additional adjustment for diabetes and cholesterol level.